Clinical trials: Rituximab, completed
Leukemia, Mucositis
Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Leukemia, Mucositis, Oral Complications
- Trial name
- UKALL14 (NCT01085617)
- Testing
- palifermin, rituximab, cyclophosphamide
- Sponsor
- University College, London
Membranous Nephropathy
Rituximab in the Treatment of Idiopathic Membranous Nephropathy
Membranous glomerulopathy (MN) is still the most common glomerular disease associated with nephrotic proteinuria (NS). Up to 40% of patients reach end stage renal failure (ESRD), making MN the 2nd or 3rd most common cause of ESRD…
- Trial name
- NCT00405340
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Non-Hodgkins Lymphoma
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
In this trial, we will evaluate the feasibility, toxicity, and effectiveness ibritumomab tiuxetan, when incorporated into combination first-line treatment for follicular lymphoma.
- Trial name
- NCT00193440
- Testing
- Rituximab, CHOP, CVP
- Volunteers
- 40 people
- Sponsor
- SCRI Development Innovations, LLC
Lymphoma
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00039195
- Testing
- filgrastim, rituximab, carboplatin
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Hodgkin's Lymphoma
Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom
To evaluate the efficacy (complete response rate) of Ybritumomab Tiuxetan (Zevalin) administration in the conditioning treatment of patients with refractory large B-cell diffuse lymphoma submitted to autologous transplantation of…
- Trial name
- Z-BEAM LDGGB (NCT00646750)
- Testing
- Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)
- Where
- 18 sites in Spain
- Volunteers
- 31 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
This is a phase I, open label, single-arm, multi-center, dose-finding study of venetoclax in combination with DA-EPOCH-R in patients with aggressive B-Cell Lymphomas.
- Trial name
- V+DA-EPOCH-R (NCT03036904)
- Testing
- Venetoclax, Rituximab, Etoposide
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- Weill Medical College of Cornell University
Lymphoma
Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma
The goals of this protocol are to determine the effect of oxaliplatin, cytosine arabinoside, and dexamethasone with Rituxan (ROAD) as treatment for patients with relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL).
- Trial name
- NCT00166439
- Testing
- Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Academic and Community Cancer Research United
Graves' Dysthyroid Ophthalmopathy, Thyroid Related Orbitopathy
Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy
This study is designed to treat patients with Graves' disease with Rituximab in an attempt to prevent or reverse the physically deforming and debilitating consequences of this disease.
- Trial name
- NCT00424151
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Silkiss, Rona Z., M.D., FACS
Non-Hodgkin's Lymphomas
The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas
This study is an open label, multicenter study with two phases: Phase I is a dose escalation study of RAD001 in combination with one injection of Rituximab 375 mg/m² per week during 4 weeks (28 days) in patients CD20 positive…
- Trial name
- (RAD001-R) (NCT01567475)
- Testing
- Everolimus and rituximab
- Where
- 5 sites in France
- Volunteers
- 21 people
- Sponsor
- The Lymphoma Academic Research Organisation
Lymphocytic Leukemia, Chronic
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with…
- Trial name
- NCT01010061
- Testing
- obinutuzumab, rituximab, chlorambucil
- Where
- 261 sites in United States, Argentina and 24 more
- Volunteers
- 787 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab and galiximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00117975
- Testing
- galiximab, rituximab
- Where
- 68 sites in United States
- Volunteers
- 62 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Rheumatoid Arthritis
Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)
This extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-Pfizer, as well as the safety and immunogenicity after transitioning from rituximab-US or rituximab-EU to rituximab-Pfizer.
- Trial name
- NCT01643928
- Testing
- Rituximab-Pfizer (PF-05280586) x 3 courses, Rituximab-EU+ Rituximab-Pfizer x 2 Courses, Rituximab-US + Rituximab-Pfizer x 2 Courses
- Where
- 71 sites in United States, Australia and 8 more
- Volunteers
- 185 people
- Sponsor
- Pfizer
Relapsed Non-Hodgkin-Lymphoma
Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma
The investigator prospectively evaluated the combination of Rituximab and Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by high dose therapy in patients with relapsed/refractory aggressive and…
- Trial name
- Mz-135 (NCT02099292)
- Testing
- Rituximab and DexaBEAM
- Volunteers
- 103 people
- Sponsor
- Georg Hess, MD
Elderly Patients (>65 Years), Diffuse Large B Cell Lymphoma (DLBCL)
R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL
The study has the purpose to compare R-CHOP versus R-mini-CEOP in elderly patients (>65 years) with Diffuse Large B Cell Lymphoma (DLBCL).
- Trial name
- ANZINTER3 (NCT01148446)
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine
- Where
- 11 sites in Italy
- Volunteers
- 226 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lupus Nephritis
Rituximab and Belimumab for Lupus Nephritis
In this experimental study, researchers will try to find out if treatment of lupus nephritis with a combination of rituximab and cyclophosphamide (CTX), or a combination of rituximab and CTX followed by treatment with belimumab…
- Trial name
- CALIBRATE (NCT02260934)
- Testing
- Rituximab, Cyclophosphamide, Prednisone
- Where
- 15 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis
Efficiency of a Tight Monitoring by a Nurse Practitioner of Rheumatoid Arthritis (RA) Patients in Remission
Rheumatoid arthritis (RA) is a progressive disease that affects mainly small and medium joints and, in the absence of appropriate background therapy, leads to progressive joint destruction, functional, psychological, social and…
- Trial name
- SIERRA (NCT03027999)
- Testing
- tight nursing follow-up
- Where
- 2 sites in France
- Volunteers
- 51 people
- Sponsor
- University Hospital, Rouen
Primary Central Nervous System Lymphoma
A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL
This is a single arm, single center, open label pilot study of Orelabrutinib combined with Rituximab, high-dose (HD) Methotrexate and Dexamethasone in newly-diagnosed primary central nervous system lymphpoma (PCNSL).
- Trial name
- ORMD2021 (NCT05036577)
- Testing
- Orelabrutinib, Rituximab, Methotrexate (MTX)
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Huashan Hospital
Lymphoma
PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
RATIONALE: Studying PET scans given to patients with cancer who are undergoing treatment may help doctors predict how patients will respond to treatment.
- Trial name
- NCT00544219
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 19 sites in Italy, Switzerland
- Volunteers
- 156 people
- Sponsor
- Swiss Cancer Institute
Mantle Cell Lymphoma
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Given the established role of high dose cytarabine (HiDAC) combined with rituximab, along with recent data showing the encouraging efficacy of bendamustine, the investigators seek to integrate the synergistic effects of these…
- Trial name
- NCT02728531
- Testing
- Bendamustine, Rituximab, Cytarabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
This is a 12-month phase 2, prospective, open label study to evaluate the effect of rituximab with mycophenolate mofetil (MMF)on the PRA of 14 highly sensitized patients who just completed an 8 month trial of MMF treatment alone.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446251
- Testing
- Rituximab, Mycophenolate mofetil (MMF)
- Volunteers
- 14 people
- Sponsor
- University of Washington
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.